Emerson strengthens leadership in life sciences industry with acquisition of fluxa

St. louis--(business wire)--emerson (nyse: emr) today announced it has acquired fluxa, a leader in the life sciences industry that uses software and modern technology architectures to accelerate the speed to market for new therapies, drugs and vaccines. the acquisition builds on emerson's leading software and solutions portfolio and life sciences expertise. emerson made an equity investment in fluxa, which is based in glendale, california, in 2021. fluxa accelerates the speed to market for new
EMR Ratings Summary
EMR Quant Ranking